YHR127W Antibody

What is YHR127W and what cellular functions has it been associated with?

YHR127W (Yhs7) is an uncharacterized protein in Saccharomyces cerevisiae that has been identified in association with nuclear mRNA ribonucleoprotein (mRNP) complexes. Based on proteomic analysis, YHR127W specifically copurifies with key mRNA-processing factors including the THO complex, Sub2, and Yra1 . This suggests potential roles in mRNA processing, packaging, or nuclear export.

The protein appears to be part of supramolecular assemblies containing hallmark components expected for nuclear mRNPs, including 5' cap-binding protein Cbp80 and 3' poly(A) tail-binding proteins Nab2 and Pab1 . Its presence in these complexes indicates it may contribute to the intricate network of interconnected proteins that package nuclear mRNPs and potentially promote RNA-RNA interactions.

How can I determine YHR127W protein expression levels in different experimental conditions?

To quantify YHR127W expression levels across different experimental conditions, researchers should consider implementing:

• Western blot analysis: Using validated YHR127W antibodies with appropriate controls (wild-type vs. YHR127W deletion strains)

• RT-qPCR: Measuring transcript levels with gene-specific primers

• Proteomics approaches: Mass spectrometry-based quantification

For Western blot optimization, consider these parameters:

When analyzing expression data, normalize to constitutively expressed proteins such as actin or TDH1 to accurately determine relative expression levels.

What critical validation steps should I perform before using a YHR127W antibody in my research?

Proper validation of YHR127W antibodies is essential for generating reliable experimental results. A comprehensive validation approach should include:

• Specificity testing: Compare signal between wild-type and YHR127W knockout/deletion strains

• Cross-reactivity assessment: Test against related yeast proteins

• Application-specific validation: Confirm functionality in your specific experimental context (Western blot, IP, IF)

• Epitope mapping: Determine which region of YHR127W the antibody recognizes

Validation should follow similar principles to those established for other research antibodies. For instance, when validating antibodies against viral or human proteins, researchers typically use multiple validation methods to ensure specificity .

Similar to antibody validation approaches in human systems, where patient samples with and without target expression are used , yeast researchers should use genetic approaches (gene deletion) to confirm antibody specificity.

How can I find reliable YHR127W antibodies using antibody repositories and search engines?

To locate validated YHR127W antibodies, leverage specialized antibody search engines and repositories:

• Antibody search engines: Use platforms like CiteAb or Antibodypedia to compare available antibodies from multiple vendors

• Data repositories: Access validation data through resources like Antibody Registry or antibodypedia.com

• Literature mining: Search publications that have used YHR127W antibodies and review their validation methods

When evaluating potential antibodies, prioritize those with:

• Experimental validation in applications similar to your planned experiments

• Published literature supporting their specificity

• Clear documentation of the immunogen used for antibody production

Consider consulting the following resources listed in comprehensive antibody databases:

How can I optimize immunofluorescence protocols to visualize YHR127W localization in yeast cells?

For successful immunofluorescence microscopy of YHR127W in yeast cells:

• Cell fixation optimization:

  • Test both formaldehyde (3-4%) and methanol fixation

  • Consider spheroplasting with zymolyase to improve antibody penetration

• Permeabilization considerations:

  • Use 0.1% Triton X-100 or 0.05% SDS to enhance antibody accessibility

  • Avoid over-permeabilization which may disrupt nuclear architecture

• Antibody incubation parameters:

  • Primary antibody: Optimize dilution (starting at 1:100 to 1:500)

  • Secondary antibody: Use highly cross-adsorbed versions to reduce background

  • Include BSA (3-5%) in blocking and antibody solutions

• Co-localization markers:

  • Nuclear markers: DAPI or Hoechst for DNA staining

  • Nuclear envelope: Anti-Nup proteins antibodies

  • mRNP markers: Anti-Nab2 or anti-Cbp80 antibodies

• Controls:

  • YHR127W deletion strain (negative control)

  • Co-staining with known interaction partners for positive reference

How can I investigate YHR127W's role in mRNP complex formation and function?

To elucidate YHR127W's contribution to mRNP biology, consider these advanced approaches:

• Proximity-dependent labeling: Employ BioID or APEX2 fusions with YHR127W to identify proteins in close proximity in living cells

• RNA-protein interaction mapping:

  • Use CLIP-seq (UV-crosslinking followed by immunoprecipitation) with YHR127W antibodies

  • Analyze RNA sequences that co-purify with YHR127W to identify binding motifs

• Structure-function analysis:

  • Generate deletion constructs of YHR127W domains

  • Assess the impact on mRNP formation using techniques like glycerol gradient fractionation

• Functional genomics:

  • Perform synthetic genetic array analysis with YHR127W deletion

  • Identify genetic interactions with known mRNA processing factors

• Advanced imaging:

  • Super-resolution microscopy to visualize YHR127W within mRNP granules

  • Live-cell imaging using fluorescently tagged YHR127W to track dynamics

These approaches can build upon the finding that YHR127W is part of nuclear mRNPs that appear to be packaged around an intricate network of interconnected proteins .

What are the challenges in detecting post-translational modifications of YHR127W using antibodies?

Detecting post-translational modifications (PTMs) of YHR127W presents several challenges:

• Modification-specific antibody development:

  • Generating phospho-specific or other PTM-specific antibodies requires synthetic peptides containing the modified residue

  • Validation is challenging due to the transient nature of many modifications

• Low abundance issues:

  • PTMs often occur on a small fraction of the total protein pool

  • Enrichment strategies (e.g., phosphopeptide enrichment) may be necessary before detection

• Specificity concerns:

  • Cross-reactivity with similar modified motifs on other proteins is common

  • Extensive controls including modification-blocking treatments are required

• Temporal dynamics:

  • PTMs may be cell cycle-dependent or stress-responsive

  • Time-course experiments with synchronized cells may be necessary

Similar to antibody validation approaches used for viral or human proteins , extensive controls including genetic and chemical approaches should be employed when studying YHR127W modifications.

How can I resolve contradictory results when analyzing YHR127W interactions using different antibody-based methods?

When facing inconsistent results across different antibody-based techniques:

• Epitope accessibility issues:

  • Different techniques expose different protein regions

  • Use antibodies targeting distinct epitopes to confirm interactions

  • Consider native vs. denatured conditions impact on epitope recognition

• Method-specific artifacts:

  • IP may detect stable interactions while proximity labeling captures transient ones

  • Cross-validation using orthogonal methods is essential

• Data integration strategy:

  • Develop a confidence scoring system weighing multiple lines of evidence

  • Consider interaction dynamics and cellular context when interpreting contradictions

What strategies can overcome low YHR127W antibody sensitivity in detecting endogenous protein levels?

To improve detection of endogenous YHR127W protein:

• Signal amplification methods:

  • Tyramide signal amplification for immunofluorescence

  • Enhanced chemiluminescence substrates for Western blots

  • Polymer-based detection systems

• Sample preparation optimization:

  • Subcellular fractionation to concentrate nuclear fractions

  • Immunoprecipitation before Western blotting (IP-Western)

  • Use of specialized extraction buffers optimized for nuclear proteins

• Technical adaptations:

  • Extended antibody incubation times (overnight at 4°C)

  • Optimized blocking agents to improve signal-to-noise ratio

  • PVDF membranes instead of nitrocellulose for better protein retention

• Genetic approaches:

  • Use of strains with upregulated YHR127W expression

  • Comparison with tagged overexpression constructs as positive controls

This approach incorporates lessons from antibody-based detection of low-abundance targets in other systems, such as viral proteins or transient human cell signaling components .